Back to results
US 2018/0021449 A1Published application
Antisense conjugates for decreasing expression of dmpk
AssigneeValerion Therapeutics, LLC
InventorDustin D. Armstrong
Life of this patent
Estimating the term…
Abstract
The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.
Claims33
A conjugate comprising
- an antisense oligonucleotide that hybridizes to a DMPK transcript;
- and
- an antibody or antigen binding fragment selected from:
- monoclonal antibody 3E10, or a variant thereof that retains the cell penetrating activity of 3E10, or a variant thereof that binds the same epitope as 3E10, or an antibody that has substantially the same cell penetrating activity as 3E10 and binds the same epitope as 3E10, or an antigen binding fragment of any of the foregoing.
1 more element
(canceled)
-9. (canceled)
-17. (canceled)
-20. (canceled)
-25. (canceled)
(canceled)
(canceled)
(canceled)
-43. (canceled)
-47. (canceled)
-55. (canceled)
-63. (canceled)
-84. (canceled)
Dependencies are inferred from the claim text.